Advances in Autoantibody Testing & Clinical Applications

Similar documents
Autoantibody Standardizing Committee

Clinical Laboratory. 14:42:00 SSA-52 (Ro52) (ENA) Antibody, IgG 1 AU/mL [0-40] Oct-18

Clinical Laboratory. [None

Clinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18

Autoantibodies giving rise to cytoplasmic IIF staining using HEp-2 cell substrate

University of Pretoria

Autoantibodies panel ANA

Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital

IdentRA test panel with eta. A clinically proven biomarker for earlier, accurate RA diagnosis and now, prognosis and monitoring

Disclosures. Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies. None

Test Name Results Units Bio. Ref. Interval

Comparison of indirect immunofluorescence and line immunoassay for autoantibody detection

Autoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic

High Impact Rheumatology

Alida R Harahap & Farida Oesman Department of Clinical Pathology Faculty of Medicine, University of Indonesia

Tools to Aid in the Accurate Diagnosis of. Connective Tissue Disease

Detection of Anti-nuclear Antibodies in Women with Hyperprolactinaemia

Test Name Results Units Bio. Ref. Interval

Assays. New. New. Combinations. Possibilities. Patents: EP , AU

Association of anti-mcv autoantibodies with SLE (Systemic Lupus Erythematosus) overlapping with various syndromes

Is it Autoimmune or NOT! Presented to AONP! October 2015!

Autoimmune (AI) Disorders

Policy. Section: Medicine Effective Date: January 15, 2015 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject:

AccuSet Autoimmune Performance Panel

VASCULITIS PRODUCT HIGHLIGHTS

NATIONAL LABORATORY HANDBOOK. Laboratory Testing for Antinuclear antibodies

What will we discuss today?

Autoantibodies in the Idiopathic Inflammatory Myopathies

Advances in Laboratory Testing for Rheumatic Diseases Updates in Testing for Rheumatic Diseases. The ABIM s view of rheumatologic lab testing

Test Name Results Units Bio. Ref. Interval

Interpreting Rheumatologic Lab Tests

Rheumatologic Testing in Primary Care

The Power of the ANA. April 2018 Emily Littlejohn, DO MPH

ANA testing can now be ordered in several ways, depending on the clinical circumstances:

Pitfalls of doing ANA immunofluorescence Can we define false positive? Can we define false negative? Can results be compared between labs?

Section: Medicine Effective Date: January 15, 2016 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject:

Policy. Background

Insights into the DX of Pediatric SLE

PS + MPs PS - MPs 37% 36% 64% 64%

INTERPRETATION OF LABORATORY TESTS IN RHEUMATIC DISEASE

Autoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens

ANA Diagnostics Using Indirect Immunofluorescence

This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma tests/panels.

Autoimmune diagnostics. A comprehensive product line for the detection of autoantibodies

Laboratory diagnosis of autoimmune diseases

Detection of serum antinuclear antibodies in lymphoma patients

Determination and distribution of various antinuclear antibodies in systemic lupus erythematosus patients by using immunoblot testing

Atlas of Antinuclear Antibodies

UPDATES ON PEDIATRIC SLE

LABORATORY STANDARDS IN THE DIAGNOSIS AND THERAPY MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS

Undifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD

Rheumatology Primer: What Labs and When

Supplementary Figure Legends

Confirmation of anti-dfs70 antibodies is needed in routine clinical samples with DFS staining pattern

IMTEC-ANA-LIA MAXX. Design Verification

Marilina Tampoia, MD; Vincenzo Brescia, MD; Antonietta Fontana, MD; Antonietta Zucano, PhD; Luigi Francesco Morrone, MD; Nicola Pansini, MD

A Multiplex Autoantibody Panel for Early Detection of Autoimmune Disease Activity

Research Article Anti-Nuclear Antibodies in Daily Clinical Practice: Prevalence in Primary, Secondary, and Tertiary Care

Dr. Venkateswari. R. Dr. Janani Sankar s unit Kanchi Kamakoti CHILDS Trust Hospital

Rheumatologic Lab Tests

ANA Diagnostics Using Indirect Immunofluorescence

Diagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016

Serum Biomarker Panel Testing for Systemic Lupus Erythematosus

Clinical & immunological characteristics in systemic lupus erythematosus patients

ANA-9-Line. Membrane based immunoblot for the semiquantitative determination of antinuclear autoantibodies. Instruction for use

Scott Vogelgesang, MD Division of Rheumatology/Immunology University of Iowa

Primary Sample Manual Immunology Issue No Effective Date: 06/11/17 Page 1 of 19 EUROFINS BIOMNIS. Pr. Conleth Feighery, Immunology Consultant

MANAGING THE PATIENT WITH POSITIVE ANA

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease

LPS CD40 + IL-4. Vorinostat (24 Hours) Vorinostat (24 Hours) Panobinostat (24 Hours) Panobinostat (24 Hours) Romidepsin (48 Hours)

.,Dr Ali Alkazzaz Babylon collage of medicine 2016

Comparison of Performance of ELISA with Indirect Immunofluoresence for the Testing of Antinuclear Antibodies

MOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism

Introduce the important components of the immune system Show how they interact & protect the body

Screening of Auto Antibodies using Indirect Immunofluorescence in Auto Immune Disease Patients

How the Innate Immune System Profiles Pathogens

HIGH ANTI-DSDNA CONTENT IN SLE IMMUNE COMPLEXES IS ASSOCIATED WITH CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT

Use of Serological markers for evaluation of patients with Rheumatoid arthritis

What your autoantibodies tell us about your disease. Mark Gourley, MD

MP Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases

Parallel Detection of Autoantibodies with Microarrays in Rheumatoid Diseases

INOVA Diagnostics, Inc., 9900 Old Grove Road, San Diego, CA , USA 2

Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases

Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus

Association of Immunofluorescence pattern of Antinuclear Antibody with Specific Autoantibodies in the Bangladeshi Population

What are Autoantibodies and how do they work in Myositis?

Development of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.

Medical Immunology Practice Questions-2016 Autoimmunity + Case Studies

Autoantibodies in the Diagnosis of Systemic Rheumatic Diseases

Understanding Autoimmune Diseases: Evolving Issues. Alvina D. Chu, M.D. April 23, 2009

Self-tolerance. Lack of immune responsiveness to an individual s own tissue antigens. Central Tolerance. Peripheral tolerance

QUANTA Lite TM ANA ELISA

What is Autoimmunity?

What is Autoimmunity?

DISCLOSURE. Relevant relationships with commercial entities none. Potential for conflicts of interest within this presentation none

Lupus Erythematosus - Can Anti-SS-A Antibody Predict the Next Event?

Rheumatology 101 A Pediatrician s Guide

ONE of the following:

Living with Lupus: An Insider s Perspective

Transcription:

Advances in Autoantibody Testing & Clinical Applications Marvin J. Fritzler PhD MD Member: IUIS-WHO-AF-CDC Serology Committee Director: Advanced Diagnostics Laboratory University of Calgary Introduction to the Autoantibody Standardization Committee (ASC) Progress in diagnostic technologies used for autoantibody detection Short overview of advances in the study of ribosomal P autoantibodies Standardization of autoantibody testing is a MAJOR ISSUE ASC Sub-Committee of the: IUIS International Union of Immunological Societies WHO World Health Organization AF Arthritis Foundation CDC Centers for Disease Control and Prevention www.autoab.org 1

ASC: Roles and Responsibilities Evaluate & make available consensus autoantibody standards through Centers for Disease Control Serve as an education, advisory and advocacy body to physicians, patients and industry Undertake and publish research studies ASC: Reference Standards ANA #1 FANA homogeneous (anti-dsdna) ANA #2 FANA speckled (anti-ss-b/la) ANA #3 FANA speckled (Sm/RNP) ANA #4 Anti-U1 RNP ANA #5 Anti- Sm ANA #6 FANA Nucleolar (anti-fibrillarin) ANA #7 Anti-SS-A/Ro ANA #8 FANA Discrete Speckled (centromere) ANA #9 Anti- Scl-70 (DNA topoisomerase I) ANA #10 Anti-Jo1 (histidyl-trna synthetase) ANA #11 Anti-PM/Scl ANA #12 Anti-Ribosomal P #13 human IgG anti-cardiolipin monoclonal #14 human IgM anti-cardiolipin monoclonal ANA #15 Anti-RNA Pol III (in progress) #16 canca (in progress) #17 Anti- cyclic citrullinated peptide CCP (in progress) www.autoab.org A Perspective on the Relative Importance of Diagnostics & Therapeutics The first line of defense in clinical medicine is prevention of disease. If prevention fails, or is not possible, a TIMELY and ACCURATE DIAGNOSIS is the next most important thing the physician can do. 2

The Patient of 2015 Complaints: Fever, rash, arthritis, chest pain, dark urine Objective findings: fever, butterfly rash, pericardial friction rub Investigations: Anemia Pericardial effusion on ECHO Proteinuria, hematuria and RBC casts Diagnosis? Will it matter? One size does not fit all THERANOSTICS Which tests do you order or do? What are the costs of not doing the right tests? 3

Autoantibody Profile Snapshot SLE Scleroderma Myositis Sjögren s Syndrome chromatin dsdna histone Sm U1-6 RNP topoisomerase I (Scl-70) RNA Pol I/III PM/Scl Jo-1 other trna synthetases Mi-2 PM/Scl SS-A/Ro 60 Ro 52 SS-B/La Muscarinic (M3) receptor Ribo P proteins assemblyosome CENP-A,-B To/Th Signal Recognition Particle Golgins GW Bodies ASE-1, HsEg5 CLIP-170 Fibrillarin B23 Exosome NuMA TS-1 RNA Cardiolipin β-2 glycoprotein I Myenteric plexus tpa-fibrin Ro 52 CENP-C? α-fodrin?? 1 patient = 1 (meaningful) autoantibody rare! Over 120 autoantibodies in SLE* Separating the wheat from chaff (Prof. Ian Mackay) Which are PREDICTIVE?** Appear before disease: Sm, CENP, cardiolipin, Ro, Ribo P Which are PATHOGENIC? dsdna nephritis Nucleosome nephritis renal failure transplant SSA60/La neonatal lupus syndrome Which are PROTECTIVE? RNP 70, CENP?? * Shoenfeld, Fritzler, et al. Sem. Arthritis Rheum. 34: 501-537, 2004 ** Harel & Shoenfeld Ann. NY Acad Sci. 1069: 322, 2006. MORE questions than answers Which are disease specific? Sm D3, C22 Ribo P, dsdna, topo I Which are organ specific? Rib P psychosis?? Relationship to MHC, SNPs Relationship to cytokines, other biomarkers? Relationship to apoptosis, necrosis, senescence, extracellular exosomes? 4

Patient Profiling - Theranostics APPROACHES INCLUDE: PROTEOMICS & BIOMARKERS Autoantibody Profile, Epitope Mapping Cytokines, Adipokines, Costimulators, Complement Receptor activation or inhibition METABOLOMICS Indicators of Disease Activity and remission GENOMICS MHC + Disease SUSCEPTIBILITY (SNPs) Markers of Disease PROTECTION Multiplexed Diagnostic Technologies Line Assays: Euroline, InnoLIA, Mikrogen Addressable Laser Bead Assays: QUANTAPlex Nanobarcodes & nanoparticles Multiplexed Lateral Flow Microfluidics: Lab on a chip Antigen/Analyte Arrays on Planar Surfaces Autoantibody Profiling in Cancer: Phage Protein Microarrays from: Wang X, et al. New England Journal of Medicine 353: 1224, 2005. 5

Autoantibodies to Ribosomes Peptide trna mrna Ribosomal P Autoantigen Ribosome Immunoblot cell extract Indirect Immunofluorescence HEp-2 cells Rib-L1 Rib-P0 Rib-P0 Rib-L77 Rib-S1 Rib-S28 Rib-L7A Rib-P1 Rib-P1 Rib-P2 Rib-P2 Rib-S4 Rib-S6 Rib-8... ~50 38 kda 19 kda 17 kda Ribosomal P Immunodominant C-terminal region P2 P1 P0 38kDa 17kDa 19kDa - stain three protein bands (IB) K V E A K K E E * S E E * S D D D M G F G L F D Mahler M, Kessenbrock K, Raats J, Williams R, Fritzler MJ, Bluthner M. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med. 2003 Mar;81(3):194-204. 6

Ribosomal P Newer assays based on the pentameric complex P1 P1 P0 P2 P2 Anti-Rib P in SLE More than 100 studies - specificity >90% Sensitivity 10 40% (geographical variable) 27.4% anti-rib-p antibody positive SLE patients are anti-dsdna negative and anti- Sm negative. Some studies have shown that anti-rib-p correlates with SLE disease activity Controversy: anti-rib-p antibodies are associated with internal organ damage (CNS, kidney, liver) or feature (NPSLE). Mahler M, Kessenbrock K, Szmyrka M, Takasaki Y, Garcia-De La Torre I, Shoenfeld Y, Hiepe F, Shun-le C, von Muhlen CA, Locht H, Hopfl P, Wiik A, Reeves W, Fritzler MJ. International multicenter evaluation of autoantibodies to ribosomal P proteins.clin Vaccine Immunol. 2006 Jan;13:77-83. Summary Rib-P Antibodies Anti-ribosomal P antibodies represent a predictive, highly disease specific and independent variable for the diagnosis and prognosis of systemic lupus erythematosus. 7

ASC Consensus Recommendation Anti-Ribosomal P should be added to anti-sm + anti-dsdna in the Classification Criteria for SLE Patient of 2015: What is the DIAGNOSIS? Will it matter?? Rib P-C22, immune complex mediated, Th2 dependant, IL-10 deficient, SNP 4p16-15.2, hrrp41 positive Acknowledgements IUIS/WHO/AF/CDC Serology Committee Chair: Dr. Pierluigi Meroni Secretary: Dr. Angela Tincani Vice-Chair: Dr. Ed Chan Dr. Michael Mahler Mark Fritzler & Jane Zhang ImmunoConcepts, INOVA Diagnostics, Euroimmun, Mikrogen, Innogenetics 8